Potassium iodide (KI) prophylaxis in the case of a nuclear accident: A new marketing authorization in France

•A first modification of the marketing authorization of “KI 65 mg, breakable tablet” for repeated prophylaxis for adults and children above 12 years old was obtained in France in 2020.•As of now, the product notice mentions the new dosage for adults and children above 12 years old as follows: one dose of 130 mg of potassium iodide per day up to 7 days, which corresponds to 2 tablets of 65 mg per day until day number 7, except if the competent authorities consider otherwise.